Keyphrases
Gefitinib
100%
Multikinase Inhibitor
100%
Brain Tumor Model
100%
Pharmacological Evaluation
100%
Brain Tumor
75%
In Vitro Study
50%
In Vivo Pharmacokinetics
50%
Further Analysis
25%
High Dose
25%
Dose Effect
25%
Akt Phosphorylation
25%
AKT1
25%
Tumor
25%
Cell Proliferation
25%
Phosphorylation
25%
Cyclin-dependent Kinase 4 (CDK4)
25%
Co-treatment
25%
Phosphoinositide 3-kinase (PI3K)
25%
IC50
25%
Platelet-derived Growth factor-BB (PDGF-BB)
25%
Platelet-derived Growth Factor Receptor (PDGFR)
25%
Tumor Accumulation
25%
Low Molecular Weight
25%
Biochemical Assay
25%
Pharmacokinetic Profile
25%
P70S6K
25%
Intravenous Dose
25%
Partition Coefficient
25%
Brain Tumor Surgery
25%
EGFR Inhibitors
25%
Negative Feedback Loop
25%
Growth Factor Receptor Tyrosine Kinase
25%
C-Raf
25%
U87 Glioma Cells
25%
Tumor Chemotherapy
25%
Synergistic Cytotoxic Effect
25%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Model
100%
Intracranial Tumor
100%
Phosphotransferase Inhibitor
100%
Gefitinib
80%
Pharmacokinetics
40%
Neoplasm
20%
Chemotherapy
20%
Protein Tyrosine Kinase
20%
Pharmacodynamics
20%
IC50
20%
Epidermal Growth Factor Receptor
20%
Growth Factor Receptor
20%
Platelet Derived Growth Factor Receptor
20%
Cytotoxicity
20%